Recently, several immune check inhibitors (ICIs), such as anti-PD-1/PD-L1/CTLA-4, have been widely applied in lung cancer, which can effectively improve progression-free survival in patients with lung cancer (29, 33, 34). This evidence concerns the gene CTLA4 and lung carcinoma.